Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN)
Conditions
Keywords
Cancer, Neural Mobilization, Graded Motor Imagery, Neuropathic pain, Nerve gliding, Chemotherapy Induced Peripheral Neuropathy, Sensory Ataxia
Brief summary
The goal of this interventional study is to learn if graded motor imagery with or without added neural mobilization can treat chemotherapy induced nerve related symptoms in lower limbs of cancer patients. The main questions it aims to answer are: \- Does graded motor imagery yields any added effects in relieving nerve related symptoms due to chemotherapy in lower limbs of cancer patients to the effects of nerve mobilization? Researchers will compare the effects of graded motor imagery as a standalone therapy (Group A) to the effects of graded motor imagery with nerve mobilization (Group B) Participants will take treatment sessions according to their allocated group, two sessions per week for six weeks.
Interventions
OTHERGraded Motor Imagery
Graded motor imagery is a series of three steps. The first step, lateral recognition, includes graded left and right judgment exercises. The second step involves imagining the performance of movements and the third, and last step involves performing movements in front of a mirror.
OTHERNeural Mobilization
Nerve mobilization allows movement between structures of nervous system and its surrounding areas. It is used to mobilize the nervous system and maintain equilibrium inside the nervous system as well as in structures present in its surroundings.
Sponsors
University of Faisalabad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
Group A was given graded motor imagery Group B was given graded motor imagery with neural mobilization
Eligibility
Sex/Gender
ALL
Age
31 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Both male and female * Age ranging from 31 to 65 years * Diagnosed cancer patients (stage 1 to 3, cancer of any kind) * Chemotherapy sessions (antineoplastic drugs) - at least 1 session * Presence of glove and stocking peripheral neuropathy * LANSS score greater than 12 * Agreed to give complete follow-up
Exclusion criteria
* Any co-morbid conditions that can cause peripheral neuropathy e.g. diabetes, chronic kidney failure * Any trauma history that can cause peripheral neuropathic symptoms * Pre-existing nerve entrapment syndromes * Diagnosed stage 4 cancer patients * Cancer patients taking palliative chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| LANSS | Baseline, week 3 (mid-intervention), week 6 (post intervention) | Leeds Assessment of Neuropathic Symptoms and Sign |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Romberg Test | Baseline, week 6 (post-intervention) | Quantitative version of Romberg Test |
| EORTC-QLQ-CIPN20 | Baseline, week 6 (post-intervention) | European Organization of Research and Treatment of Cancer-Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20 |
Countries
Pakistan
Outcome results
None listed